Sugi Predict

Sugi Predict / Compounds / SCHEMBL553919

SCHEMBL553919

SCHEMBL553919

CC(C)(C)OC(=O)N1CCO[C@@H](CO)C1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ PDK1 Q15118 5/20 0.50
▸ NR1H2 P55055 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ HPGD P15428 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ EPHA2 P29317 3/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ ERBB2 P04626 1/20 0.39
▸ EPHB4 P54760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304803 1.00 USP2 (0.53) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL304804 1.00 USP2 (0.53) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL8904969 1.00 USP2 (0.53) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL306580 0.91 PDK1 (0.52) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL305277 0.91 PDK1 (0.52) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL305278 0.91 PDK1 (0.52) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL29864929 0.91 RECQL (0.49) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL30987096 0.90 HPGD (0.49) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL1655537 0.88 USP2 (0.50) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL31040994 0.88 USP2 (0.50) USP2SMN1; SMN2PDK1NR1H2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955422-A Synthesis method of 2- (R) -hydroxymethyl morpholine-N-tert-butyl formate 常熟泓德生物科技有限公司 2024-11-15 — — CN claimed
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 — — WO claimed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-12606550-B2 Methods for synthesis of CHK1 inhibitors CRT PIONEER FUND LP (GB) 2026-04-21 — — US disclosed
US-12570672-B2 Macrocyclic compounds and methods of use AMGEN INC. 2026-03-10 — — US disclosed
US-20260049080-A1 WILD TYPE KIT INHIBITORS BLUEPRINT MEDICINES CORP (US) 2026-02-19 — — US disclosed
EP-4695259-A1 TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2026-02-18 — — EP disclosed
EP-4695228-A1 SYNTHESIS OF RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-18 — — EP disclosed
EP-3959211-B1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS BAYER AG (DE) 2026-02-18 — — EP disclosed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
WO-2004054514-A2 C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-07-01 — — WO disclosed
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-19 — — US disclosed
US-5698685-A Morpholino-subunit combinatorial library and method ANTIVIRALS INC. (US) 1997-12-16 — — US disclosed
US-5506337-A Morpholino-subunit combinatorial library and method ANTIVIRALS INC. (US) 1996-04-09 — — US disclosed
CN-1107151-A Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders SANKYO CO (JP) 1995-08-23 — — CN disclosed
CN-1028527-C Process for preparing coumarin derivatives SANKYO CO (JP) 1995-05-24 — — CN disclosed
EP-0411912-B1 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders SANKYO CO (JP) 1995-04-19 — — EP disclosed
CN-1049662-A Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder SANKYO CO (JP) 1991-03-06 — — CN disclosed
EP-0411912-A2 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders Sankyo Company Limited (JP) 1991-02-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 USP2 740/4885SMN1; SMN2 1781/4885PDK1 590/4885
US-20260049080-A1 WILD TYPE KIT INHIBITORS KIT, CSNK1A1, CSNK1A1L USP2 2839/4885SMN1; SMN2 2675/4885PDK1 524/4885
US-12606550-B2 Methods for synthesis of CHK1 inhibitors CHEK1, CHEK2, RAD1 USP2 1479/4885SMN1; SMN2 2164/4885PDK1 466/4885
US-12570672-B2 Macrocyclic compounds and methods of use KRAS, NRAS, BRAF USP2 3246/4885SMN1; SMN2 1780/4885PDK1 1342/4885
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS TACR1, NPSR1, SSTR2 USP2 3514/4885SMN1; SMN2 4534/4885PDK1 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.